Hungaryʼs Culevit wins HUF 103 mln EU funding for R&D
Hungary-based Culevit has been awarded a HUF 103 million European Union grant to help a HUF 180 mln research and development project, according to a press statement sent to the Budapest Business Journal on Wednesday.
The company, which makes nutritional supplements for cancer patients, is planning to use the money for R&D supporting the expansion of Culevit products on offer, with the chief aim of meeting the demands of Hungarian patients, the press statement said. The company added that the support will also help provide a basis for the company’s expansion with its products abroad.
“R&D has been one of the basic pillars of Culevit from the beginning,” said Culevit CEO Dr. László Lex. “R&D is obviously carried out even when we are not supported with grants, but using external sources we can realize our development plans in a shorter time,” the CEO added.
The company posted revenues of HUF 684 million in 2015, Hungarian news agency MTI reported, adding that it employs 22 people.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.